Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5213 for Sleep in Mild Alzheimer's and MCI
NCT01548287Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2012
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of azd5213 in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by AstraZeneca. Primary endpoint: Total Sleep Time (PSG) at 4 weeks. Started Apr 2012; status: completed.
02
Drugs
azd5213
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT01548287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01548287.